Mister Spex (MRX) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
12 Nov, 2026Executive summary
9M 2026 revenue was €133.580m, down 8% YoY; Q3 revenue decline narrowed to 4% as offline growth partly offset online weakness.
9M adjusted EBITDA rose to €5.746m from €4.5m; Q3 adjusted EBITDA was €1.902m versus €2.1m.
Logistics and prescription-glasses production shifted to partners, while Salesforce integration expanded to marketing and customer service.
Financial highlights
Q3 revenue was €45.720m, down 4% YoY; gross profit was €24.7m versus €26.0m.
Q3 adjusted EBITDA was €1.902m versus €2.1m; reported EBITDA improved to €0.7m from -€0.7m as adjustments fell 59% to €1.2m.
Q3 EBIT loss narrowed to €3.4m from €4.6m and net loss to €3.9m from €5.0m.
9M gross profit was €74.721m, down 6%; gross margin rose to 55.9% from 54.9%. Q3 gross margin was 54.0%, down 74 bps.
Personnel expenses declined 5% and other operating expenses 15%, partly offsetting lower Q3 gross profit.
Outlook and guidance
FY2026 revenue guidance remains 0% to -10%; adjusted EBITDA margin guidance is break-even to mid-single digits.
Year-end cash guidance was reduced to €21m–€23m from €25m–€30m, reflecting lower operating cash generation, working-capital buildup and accelerated transformation costs.
Q4 is expected to bring a slight working-capital increase and non-recurring effects in the high-single-digit-million-euro range.
With flat revenue in 2027, significant profitability improvement is expected, conditional on timely implementation of transformation and productivity initiatives.
Latest events from Mister Spex
- Adjusted EBITDA up 65% to €3.8m, gross margin 56.9%, offline revenue up 10%, revenue down 10%.MRX
Q2 2026 - Q1 2026 saw earnings and margin gains, led by offline growth and strategic shifts, despite revenue decline.MRX
Q1 2026 - Margin expansion and profitability inflection achieved, with EBIT loss reduced by €59m.MRX
Q4 2025 - Q3 2025 revenue fell 18%, but gross margin and EBIT improved sharply amid ongoing transformation.MRX
Q3 2025 - Gross margin rose to 55.0% as cost discipline offset revenue declines and losses narrowed.MRX
Q2 2025 - Gross margin rose to 48.8% as restructuring drove losses and international sales fell 17%.MRX
Q3 2024 - Profitability challenges prompt transformation and rebranding amid modest revenue growth.MRX
H1 2024 - Gross margin rose to 56.4% and EBIT loss narrowed, despite a 13% revenue drop.MRX
Q1 2025 - Restructuring led to a 3% revenue drop and wider losses in 2024; EBIT to improve in 2025.MRX
H2 2024